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Abstract
Background: Time to detection (TTD) on automated liquid mycobacterial cultures is an emerging biomarker of tuberculosis
outcomes. The M. tuberculosis W-Beijing genotype is spreading globally, indicating a selective advantage. There is a paucity
of data on the association between baseline TTD and W-Beijing genotype and tuberculosis outcomes.
Aim: To assess baseline predictors of failure of sputum culture conversion, within the first 2 months of antitubercular
therapy, in participants with pulmonary tuberculosis.
Design: Between May 2005 and August 2008 we conducted a prospective cohort study of time to sputum culture
conversion in ambulatory participants with first episodes of smear and culture positive pulmonary tuberculosis attending
two primary care clinics in Cape Town, South Africa. Rifampicin resistance (diagnosed on phenotypic susceptibility testing)
was an exclusion criterion. Sputum was collected weekly for 8 weeks for mycobacterial culture on liquid media (BACTEC
MGIT 960). Due to missing data, multiple imputation was performed. Time to sputum culture conversion was analysed using
a Cox-proportional hazards model. Bayesian model averaging determined the posterior effect probability for each variable.
Results: 113 participants were enrolled (30.1% female, 10.5% HIV-infected, 44.2% W-Beijing genotype, and 89% cavities). On
Kaplan Meier analysis 50.4% of participants underwent sputum culture conversion by 8 weeks. The following baseline
factors were associated with slower sputum culture conversion: TTD (adjusted hazard ratio (aHR) = 1.11, 95% CI 1.02; 1.2),
lung cavities (aHR= 0.13, 95% CI 0.02; 0.95), ever smoking (aHR= 0.32, 95% CI 0.1; 1.02) and the W-Beijing genotype
(aHR= 0.51, 95% CI 0.25; 1.07). On Bayesian model averaging, posterior probability effects were strong for TTD, lung
cavitation and smoking and moderate for W-Beijing genotype.
Conclusion: We found that baseline TTD, smoking, cavities and W-Beijing genotype were associated with delayed 2 month
sputum culture. Larger studies are needed to confirm the relationship between the W-Beijing genotype and sputum culture
conversion.
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Introduction
Tuberculosis cure after anti-tubercular therapy is best measured
by bacteriological relapse within 2 years after completion of
treatment. Because relapse is uncommon after short course
therapy large sample sizes are required to detect differences in
relapse rate, which, together with extended follow up periods,
makes clinical trials using relapse as the primary endpoint very
expensive. Sputum culture conversion after 2 months of treatment
is a recognized surrogate biomarker of cure [1,2]. Time to
detection (TTD) on automated liquid mycobacterial cultures
reflects mycobacterial load more accurately than sputum smear or
culture grading, and has been shown to predict month 2 culture
conversion, tuberculosis recurrence and relapse [3,4].
Important factors associated with smear and culture non-
conversion after 2 months include increasing age, chest radio-
graphic features (cavitation and extent of disease), and higher
sputum smear and culture grading at diagnosis [5–10].
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There is limited evidence on the influence of M. tuberculosis
genotype on the clinical outcome of tuberculosis. It has been
suggested that the W-Beijing genotype has a selective advantage
over other M. tuberculosis strains, since it is emerging worldwide and
is linked to multidrug resistance in many areas [11,12]. Data is
conflicting regarding the role of the W-Beijing genotype on the risk
of treatment failure or relapse [13–16].
We assessed baseline predictors, including W-Beijing genotype,
of failure of sputum culture conversion within the first 2 months in
participants with first episodes of smear positive pulmonary
tuberculosis attending a primary care centre in Cape Town,
South Africa.
Methods
Ethics statement
The trial protocol was approved by the University of Cape
Town Ethics and Research Committee and written consent was
obtained from all participants.
Study population and setting
Participants with first episodes of sputum smear positive
pulmonary tuberculosis were enrolled in a randomized controlled
trial of a micronutrient intervention (vitamin A and zinc), which
has been reported elsewhere [17]. In brief, adults who attended
two primary care tuberculosis clinics in Delft, Cape Town, South
Africa between May 2005 and August 2008 were recruited. Rates
of poverty and unemployment are high in Delft and the
tuberculosis incidence rate increased from 496 to 737 cases per
100 000 during the study period. Study participants received
standard anti-tubercular therapy for 5 days a week consisting of
combination tablets contributing 600 mg rifampicin, 300 mg
isoniazid, 1.6 g pyrazinamide and 1.1 g ethambutol for partici-
pants weighing 38 to 55 kg (Rifafour, Aventis Pharma Pty Ltd,
Johannesburg). Doses were adjusted for participants weighing less
than 38 kg or more than 55 kg. All participants were on directly
observed therapy at the clinic or in the community. Research staff
collected early morning sputum specimens weekly from partici-
pants for 8 weeks. The micronutrient intervention had no effect on
. time to sputum smear or culture conversion up to 8 weeks on
Kaplan Meier analysis (P=0.15 and P=0.38 respectively; log rank
test) The current analysis is restricted to trial participants with a
positive baseline sputum culture and with data on susceptibility to
rifampicin and isoniazid. Participants with rifampicin resistance
during the 8 week follow-up period, were excluded.
Study procedures and selection of isolates
In keeping with national guidelines at the time, none of our
HIV-infected participants received anti-retroviral therapy, but all
received co-trimoxazole prophylaxis. All participants were
screened for misuse of alcohol with the Cut down, Annoyance,
Guilt and Eye-opener (CAGE) questionnaire [18]. Smoking status
was categorized as either never or ever smoked. Body weight and
height of participants was determined. The extent and size of lung
cavities at baseline was assessed independently by two pulmonol-
ogists experienced in the use of the Chest Radiograph Reading
and Recording System (CRRS)- and disagreements on radio-
graphic reading were resolved by consensus [19].
Prior to anti-tubercular therapy, trial participants supplied one
spontaneous sputum specimen and thereafter one early morning
unassisted sputum specimen every week, up to 8 weeks. Sputum
specimens were examined by means of fluorescent microscopy
(Auramine stain) and graded according to international standards
[20]. All specimens were decontaminated and cultured on liquid
media using the BACTEC MGIT 960 system (Becton Dickinson,
Sparts, Maryland). Positive cultures were confirmed as M.
tuberculosis complex using an in-house PCR assay [21]. The date
of culture conversion was taken as the date of the first negative
culture provided there were no subsequent positive cultures.
Participants whose first negative culture occurred at week 8, were
regarded as converters. Routine phenotypic drug susceptibility
testing for isoniazid and rifampicin of isolates was carried out using
the MGIT 960 system from January 2008; isolates cultured prior
to that date were tested retrospectively, but some isolates had lost
viability.
During 2009, spoligotyping was performed on the majority of
serial isolates collected during the trial period [22]. Strain-specific
PCR assays were performed to detect M. tuberculosis infections by
W-Beijing and non-W-Beijing isolates [23]. In order to optimize
the baseline data, we captured the strain type for all the available
baseline isolates, as well as those within the first 2 weeks of
treatment, in order to categorize participants as either W-Beijing
or non-W-Beijing strain types. Ten participants who had two
strain types, one of which was W-Beijing, were categorized as
having the W-Beijing strain for the analysis.
Statistical analysis
Data was captured in duplicate in Microsoft Office Excel 2003
and validated with SAS 9.2 software. To account for missing data,
multiple imputation was conducted with the Amelia II software
package [24],a reliable imputation procedure implemented in the
statistical software package R,and five imputed data sets were
generated. This number of data sets is generally considered
adequate [25].
Cox proportional hazard regression modeling with the imputed
datasets was used to estimate the hazard ratio of culture conversion
for the following pre-determined baseline variables: age, gender,
smoking status, alcohol abuse, sputum smear grading, sputum
TTD, presence and extent of cavitation, M. tuberculosis genotype,
HIV-infection, body mass index, haemoglobin, total lymphocyte
count, serum C-Reactive Protein (CRP) (at baseline and change in
concentrations within the first 2 weeks) and albumin. Hazard ratios
are reported together with 95% confidence intervals based on
Rubin’s rules [25]. The proportional hazards assumption was
verified by testing interaction effects of analysis time with baseline
variables (a=0.05) and graphically via log-log-plots [26].
To confirm the stability of our results we conducted a sensitivity
analysis using Bayesian model averaging to each imputed data set
(M=20), and the results were combined by Rubins’ rules [25,27].
Model averaging is an alternative to model selection and combines
estimates from different models, which contain different sets of
variables, with the aim of achieving stable estimates that incorporate
modelling uncertainty in addition to sampling uncertainty: Models
that have a higher posterior probability to be correct receive a
higher weight [26]. The combined weighted estimates can then be
interpreted as a stabilized hazard ratio of culture conversion, which,
together with adjusted standard errors, reflects the uncertainty in
the modeling process. The posterior effect probabilities presented in
our analysis state the probability that the hazard ratio in the Cox
regressionmodel for a variable is not one, thus providing a summary
measure of how likely it is that a baseline variable has an effect and
ranks the importance of the baseline variables.
Results
Baseline characteristics
A total of 154 participants with new smear-positive pulmonary
tuberculosis were enrolled in the micronutrient trial, of whom 113
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fulfilled the inclusion criteria for the current study (Fig. 1). Four of
the 113 sputum isolates were mono-resistant to isoniazid.
Complete data on all the variables investigated in the current
analysis was available in 72 patients. The baseline characteristics
of these participants before and after multiple imputation, is shown
in Table 1. There were 11 HIV-infected participants (5 males, 6
females) and HIV-status was not determined in 9 who were lost to
follow-up before the test could be done. All participants underwent
chest radiograph examination at baseline, but 22 could not be
located at the clinic site either due to mis-filing or loss (e.g. chest
radiographs sent with participants who were referred to hospitals).
Strain data was unavailable for seven participants whose sputum
cultures were discarded before spoligotyping could be performed.
Participants had a high baseline bacillary burden, as reflected by
the large proportion with a high sputum smear grading and a short
median duration of TTD of 7 days (Table 1). Lung cavities were
common and there was a high prevalence of smoking and alcohol
abuse among participants. Spoligotyping showed that almost half
of our participants had the W-Beijing strain type.
By week 6, nine percent of participants were lost-to follow-up and
by week 8, this increased to 15%. Two cultures from participants
who had not undergone culture conversion up to week 7, had
contaminated cultures at week 8 and were categorized as not having
converted. On Kaplan Meier analysis 50.4% of participants had
undergone culture conversion by 8 weeks (data not shown).
Predictors of delayed sputum culture conversion
Cox-proportional hazard regression analysis showed that TTD,
the presence of lung cavities at diagnosis and ever smokers, were
all associated with delayed culture conversion in univariate
analysis. After adjustment for co-variates, TTD and lung cavities
remained significant (Table 2). Although the W-Beijing genotype
was not significant in univariate analysis, the confidence interval
was suggestive of a delayed effect on conversion, even after
adjustment for co-variates. INH mono-resistance was not
associated with conversion in univariate analysis (HR=0.59;
95%CI, 0.082; 4.28) and was not explored further due to the
limited number of participants.
The estimated hazard ratios of the variables remained similar
after model averaging (estimates not shown) confirming the
stability of our main results. After Bayesian model averaging ever
smokers, the presence of lung cavities and TTD had a posterior
effect probability of greater than 80%, thus having a rather strong
effect on sputum conversion, even after taking model uncertainty
into account. A moderate effect of W-Beijing genotype was also
present (Table 2).
Discussion
We found that a shorter baseline TTD, tobacco smoking, the
presence of lung cavities and W-Beijing genotype were associated
with delayed sputum culture conversion within the first 2 months
in adults with smear-positive pulmonary tuberculosis. Bayesian
model averaging showed that TTD, lung cavitation and smoking
had strong effects and the W-Beijing genotype a moderate effect.
The association we found between W-Beijing and sputum culture
conversion has only been reported previously among a small
number of participants, who participated in a multicentre trial
[28]. Our finding that a shorter TTD is associated with delayed
culture conversion adds to the very limited data on this potential
surrogate marker [3,4]. An increase of 3 days in TTD at baseline
was associated with a 40% increase in the likelihood of conversion.
Cavitation is a well- known factor associated with delayed sputum
culture conversion [3,5] and relapse [29].
Figure 1. Participant selection from the parent micronutrient trial for the sputum culture conversion analysis.
doi:10.1371/journal.pone.0029588.g001
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Our data suggests that W-Beijing strains may be associated with
delayed sputum culture conversion within the first 2 months, after
adjusting for baseline bacillary load, the presence of lung cavities
and the effect of smoking. Since the association between W-Beijing
and culture conversion was largely unaffected by the adjustment
for bacillary load at diagnosis and cavitatory disease, it suggests
that other factors such as the host response to anti-tubercular
treatment, may be important. Almost half of our participants had
the W-Beijing genotype at baseline or within the first 2 weeks of
treatment. The proportion of W-Beijing strains reported among
adults and children with tuberculosis in Cape Town has ranged
from 17 to 33% [30–32] and data from a paediatric referral
hospital shows a marked increase in the prevalence of W-Beijing
strains among children with tuberculosis between 2000 and 2003
[32]. One of the properties accounting for the rapid spread of the
W-Beijing strains in our area may be operating by prolonging
transmission in treated patients.
There is conflicting data on the role of smoking in sputum
culture conversion [33]. Our unadjusted analyses showed that ever
smokers had a significant longer time to culture conversion,
compared with never-smokers during the first 2 months of
treatment (HR=0.45 (95% CI: 0.25–0.82)). This finding is similar
to that of two other clinical trials [3,34]. Retrospective data show
that smokers are more likely to have clinical symptoms of
tuberculosis such as cough and dyspnoea, as well as cavitary
lesions, compared with non-smokers [35,36]. When we adjusted
for the presence of cavities and other confounders, the statistical
significance of ever smoking was somewhat reduced, but smoking
still had a strong effect in the final model, confirmed by model
averaging estimates.
We were not able to demonstrate any significant effect of either
baseline CRP concentrations, or change in concentrations after 2
weeks on treatment, on the risk of sputum culture conversion.
CRP is a non-specific acute phase reactant and a marker of
Table 1. Baseline characteristics of participants with drug sensitive smear-positive pulmonary tuberculosis.#
Characteristic Before multiple imputation After multiple imputation
n
Age, years 113 30.0 (22.0–43.0) NA
Sex 113
Female 34 (30.1%) NA
Male 79 (69.9%)
HIV-status 104
Positive 11 (10.5%) 10.8% (95% CI:5.0; 16.6)
Negative 93 (89.4%) 89.2% (95% CI:83.4; 95.0)
Treatment group 113
Micronutrient 56 (49.6%) NA
Placebo 57 (50.4%)
Sputum smear grade 113
Scanty positive 1 (0.9%) NA
1+ 10 (8.9%)
2+ 13 (11.5%)
3+ 89 (78.8%)
Time to culture detection, days 113 7.0 (6.0–11.0) NA
M. tuberculosis genotype 106
W-Beijing 50 (44.2%) 46.5% (95% CI:37.2; 55.9)
Other 56 (52.8%) 53.5% (95% CI:44.1; 62.3)
Chest radiograph 91
Lung cavities 81 (89.0%) 88.1% (95% CI:82.1; 94.2)
No. of lung zones affected by cavities 2.0 (1.0–2.0) 1.8 (1.0–2.6)
Body Mass Index, (kg/m2) 112 18.9 (17.5–21.2) 18.9 (17.5–21.2)
Cigarette smoking 113
Ever 85 (75.2%) NA
Never 28 (24.8%)
Alcohol misuse 113 43 (38.1%) NA
Haemoglobin (g/dl) 111 12.1 (10.75–12.9) 12.03 (10.7–12.9)
Albumin (g/l) 111 36.9 (33.2–38.6) 36.86 (33.18–38.6)
C-Reactive protein (mg/l) 103 53.6 (36.4–75.8) 53.7 (36.6–75.8)
Total Lymphocyte count (6109/l) 113 1.8 (1.35–2.24) NA
#Continuous data expressed as median (IQR).
NA: Not applicable. Data was complete, therefore not imputed.
doi:10.1371/journal.pone.0029588.t001
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macrophage activation in active tuberculosis that is increased at
diagnosis in proportion to the extent of disease and decreases
during and after treatment [37–39]. Pre-treatment serum CRP
concentrations have a high sensitivity for the diagnosis of active
tuberculosis among smear-negative tuberculosis suspects [40] and
was recently shown to be a risk factor for sputum smear conversion
among participants in a micronutrient trial in Nigeria [9].
Our study has several limitations. First, there were missing
observations in our data. We dealt with this by imputing missing
data, which has been shown to be superior to complete case
analysis (in which only subjects with no missing values are
analyzed). If data is missing at random, it means that the
missingness of data depends on observed co-variables or the
outcome [41]. We find this assumption reasonable in our study,
since the missing data related mainly to data capturing issues.
Therefore, multiple imputation yields unbiased estimates that
correctly reflect the uncertainty related to the missing data.
Second, a large proportion of our study participants did not
convert during the 2 month period (49.6%), resulting in less
statistical power. Similar high rates of culture positivity have been
observed at 2 months at African sites using liquid culture media
[4,9,42]. One of the strengths of our analysis is that we measured
the time to sputum culture conversion, instead of a binary
endpoint of culture conversion. Third, we did not assess the
presence of a BCG scar among our participants. The absence of a
BCG scar was recently shown to be an important factor in culture
non-conversion among a Tanzanian cohort [8]. On the contrary,
it has been suggested that the widespread use of the BCG vaccine
may aid in the spread of W-Beijing strains, since it offers poor
protection against W-Beijing strains in experimental models [11].
The BCG coverage among our local infants is high (99%) [43].
Fourth, rates of smoking and alcohol misuse were high in our
study, but similar to those reported in another study from our
region [4]. Variables associated with sputum conversion may be
different in populations with lower rates of smoking and alcohol
abuse.
Delayed sputum culture conversion increases the risk of relapse
and prolongs the period of infectiousness. Therefore our findings
about factors delaying culture conversion have several implications
for public health. Smoking is associated with many health hazards,
including increasing the risk of developing active tuberculosis [33].
Global tobacco use is increasing [44] and remains high in most
countries with a high burden of tuberculosis [45,46]. Effective
tobacco control measures are needed, particularly in low-income
countries, where smoking rates are highest among poorer and less
educated communities [47]. Earlier detection of tuberculosis
should reduce the number of patients presenting with cavitary
disease and those with a higher sputum bacillary load and thus
contribute to earlier sputum conversion. Finally, as mentioned
above, BCG vaccination offers particularly poor coverage of W-
Beijing strains. Newer tuberculosis vaccines will hopefully have
greater activity against all strains, including W-Beijing.
In conclusion, a shorter baseline TTD, tobacco smoking, the
presence of lung cavities, and W-Beijing genotype were associated
with delayed sputum culture conversion within 2 months in adults
with smear-positive pulmonary tuberculosis. Larger studies in
high-burden settings are needed to confirm the relationship
between the W-Beijing genotype and sputum culture conversion.
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